Annals of hematology · 2013
Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tovar Natalia, Fernández de Larrea Carlos, Pedrosa Fabiola, Aróstegui Juan I, Cibeira Ma Teresa, Rosiñol Laura, Elena Montserrat, Filella Xavier, Yagüe Jordi, Bladé Joan
Аннотация
Heat-shock proteins (HSP) are important molecules in the pathogenesis of multiple myeloma (MM). Their blockages by drugs or cellular immune response have been investigated, and a possible association with the presence of oligoclonal bands (OB) has been postulated in patients with MM after allogenic stem cell transplantation. The aim of the present study was to ascertain the serum antibody levels against three HSP (60, 70 and 90) by ELISA in patients with MM in complete remission after autologous stem cell transplantation (ASCT), with or without OB, and compare them with those patients with stable gammopathy of undetermined significance (MGUS) and healthy controls. Our results in samples after ASCT showed no differential levels of anti-HSP according to the presence or absence of the oligoclonal response. However, higher levels of anti-HSP90 were found in patients with stable MGUS in comparison with MM patients (p = 0.004). In the same line, a longer progression-free survival was observed in those patients who presented higher anti-HSP90 levels after ASCT (p = 0.042). These results suggest, for first time, the potential of anti-HSP90 humoral immune response for long-term control of malignant plasma cell disorders.
Предметные рубрики MeSH
AdultAgedAntibodies, NeoplasmAntibody SpecificityAntineoplastic Combined Chemotherapy ProtocolsAutoantibodiesAutoantigensBoronic AcidsBortezomibChaperonin 60Combined Modality TherapyDisease-Free SurvivalEnzyme-Linked Immunosorbent AssayFemaleGlucocorticoidsHSP70 Heat-Shock ProteinsHSP90 Heat-Shock ProteinsHematopoietic Stem Cell TransplantationHumansMaleMelphalanMiddle AgedMonoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaNeoplasm ProteinsOligoclonal BandsPyrazinesRemission InductionThalidomideTransplantation, Autologous